The sales are routine and likely driven by tax or liquidity needs following the director stock grants. No bearish read-through. Monitor for any C-suite insider sales or a material increase in sale volume (>0.5% of market cap) before adjusting stance.
KROS drugs
KROS drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jun 9 $10.07entry
- T+1 · 5mo ago −1.39%α +0.19% · $9.93
- T+5 · 5mo ago +1.69%α −0.72% · $10.24
- T+20 · 4mo ago +15.69%α +14.24% · $11.65
- T+60 · 3mo ago +11.52%α +7.71% · $11.23
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Two Keros Therapeutics directors sold a combined $56K in open-market sales on June 4, 2026, following a round of non-cash stock grants to the same directors on June 3. The sales are trivial relative to the $204M market cap (0.03%) and are likely liquidity-driven after the grants, not a bearish signal. The cluster is not amplified by any cross-filing context (no earnings, offering, or late-filing events nearby).
Key Financial Metrics
Key Facts
- Two directors (Seth Alpna and Knowles Julius) each sold 2,625 shares on June 4, 2026, at ~$10.72-$10.73, totaling $56,306.
- Both sales occurred one day after each director received non-cash stock grants (7,433 and 7,142 shares respectively) on June 3, 2026.
- Total sale value of $56K represents only 0.03% of KROS's $204M market cap, well below the 0.1% materiality threshold.
- No C-suite executives participated in the sales; only two directors sold.
- No recent earnings, offering, restructuring, or late-filing events are present to amplify the cluster's signal.
Financial Impact
Total open-market sales of $56,306, or 0.03% of market cap, immaterial.
Risk Factors
- If additional insiders (especially C-suite) begin selling in the coming weeks, the pattern could become more concerning.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-KROS-1780951066902 |
Track record
27 reports on KROS
4 of 4 bullish or bearish reports moved the stock their way by T+20. Best: +12.51% at T+60 after the Jul 30, 2026 report. 4 of 4 went positive at some point.
Filters
- Nov 16, 2026today Press Release Neutral 2/10 Entry $10.03 Now $10.03 −0.00% settles Dec 16
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $10.30 Now $10.03 −2.62% settles Dec 14
- Nov 5, 202611d ago 8-K Neutral 3/10 Entry $9.36 Now $10.03 +7.16% settles Dec 7
- Nov 5, 202611d ago 8-K Neutral 5/10 Entry $9.36 Now $10.03 +7.16% settles Dec 7
- Nov 5, 202611d ago Press Release Neutral 5/10 No price data
- Oct 27, 202620d ago SC 13G/A Neutral 3/10 Entry $11.61 Now $10.03 −13.61% settles Nov 25
- Sep 29, 20266w ago 8-K Bullish 6/10 Entry $11.19 to $11.43 Now $10.03 −10.37% ▲ +2.10% +1.39% vs SPY
- Sep 28, 20267w ago 8-K Neutral 4/10 Entry $11.28 to $11.33 Now $10.03 −11.08% ▲ +0.44% +0.47% vs SPY
- Sep 28, 20267w ago Press Release Neutral 3/10 Entry $11.28 to $11.33 Now $10.03 −11.08% ▲ +0.44% +0.47% vs SPY
- Sep 17, 20268w ago EFFECT Neutral 3/10 Entry $11.36 to $11.10 Now $10.03 −11.71% ▼ −2.29% −3.49% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers